BNP Paribas Financial Markets Sells 81,416 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

BNP Paribas Financial Markets lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 14.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 484,560 shares of the biopharmaceutical company's stock after selling 81,416 shares during the period. BNP Paribas Financial Markets owned 0.16% of Amicus Therapeutics worth $4,565,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Covestor Ltd raised its holdings in Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 2,312 shares during the last quarter. R Squared Ltd acquired a new position in Amicus Therapeutics during the fourth quarter worth $79,000. KBC Group NV raised its holdings in Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the last quarter. Sciencast Management LP acquired a new position in Amicus Therapeutics during the fourth quarter worth $100,000. Finally, Stephens Inc. AR acquired a new position in Amicus Therapeutics during the fourth quarter worth $101,000.

Amicus Therapeutics Stock Performance

FOLD traded up $0.48 during trading on Friday, hitting $6.43. 8,141,440 shares of the company traded hands, compared to its average volume of 2,809,213. The firm has a market cap of $1.98 billion, a P/E ratio of -35.72, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64. The stock's fifty day moving average is $7.37 and its 200 day moving average is $8.92. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a one year low of $5.81 and a one year high of $12.65.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Wells Fargo & Company lowered their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. UBS Group upped their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group reduced their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.